共 181 条
[1]
Tilly H(2015)Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol. 26 10-2544
[2]
Neelapu SS(2017)Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma N Engl J Med. 377 2531-55
[3]
Locke FL(2019)Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management Blood Rev. 34 45-3058
[4]
Bartlett NL(2014)Role of imaging in the staging and response assessment of lymphoma: consensus of the international Conference on Malignant Lymphomas Imaging Working Group J Clin Oncol. 32 3048-1405
[5]
Lekakis LJ(2020)High total metabolic tumor volume at baseline predicts survival independent of response to therapy Blood. 135 1396-5615
[6]
Miklos DB(2020)Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma Blood Adv 4 5607-962
[7]
Jacobson CA(2022)[18F]FDG PET-CT in patients with DLBCL treated with CAR-T cell therapy: a practical approach of reporting pre- and post-treatment studies Eur J Nucl Med Mol Imag. 49 953-45
[8]
Brudno JN(2020) F-FDG PET dissemination features in diffuse large B-cell lymphoma are predictive of outcome J Nucl Med. 61 40-411
[9]
Kochenderfer JN(2021)Risk stratification in diffuse large B-cell lymphoma using lesion dissemination and metabolic tumor burden calculated from baseline PET/CT† Ann Oncol. 32 404-1932
[10]
Barrington SF(2022) F-FDG PET maximum-intensity projections and artificial intelligence: a win-win combination to easily measure prognostic biomarkers in DLBCL patients J Nucl Med. 63 1925-4789